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Background: Circulating enterovirus 71 (EV-A71)-associated hand, foot, and mouth disease is on the rise in the
Asian-Pacific region. Although animal models have been developed using mouse-adapted EV-A71 strains, mouse
models using primary EV-A71 isolates are scarce. Lethal animal models with circulating EV-A71 infection would
contribute to studies of pathogenesis as well as vaccine development and evaluation.
Results: In this study, we established a lethal mouse model using primary EV-A71 isolates from patients infected
with serotypes that are currently circulating in humans. We also characterized the dose-dependent virulence and
pathologic changes of circulating EV-A71 in this mouse model. Most importantly, we have established this mouse
model as a suitable system for EV-A71 vaccine evaluation. An inactivated EV-A71 vaccine candidate offered
complete protection from death induced by various circulating EV-A71 viruses to neonatal mice that were born to
immunized female mice. The sera of the immunized dams and their pups showed higher neutralization titers
against multiple circulating EV-A71 viruses.
Conclusions: Thus, our newly established animal model using primary EV-A71 isolates is helpful for future studies
on viral pathogenesis and vaccine and drug development.
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Human enterovirus 71 (EV-A71) is a non-enveloped,
single-stranded positive-sense RNA virus that belongs to
the Enterovirus species A genogroup in the Picornaviri-
dae family. It began circulating in the Netherlands as
early as 1963 and was first described in the USA in 1969
[1, 2]. EV-A71 and Coxsackievirus A16 (CV-A16) are
the two major etiological agents that cause hand, foot,
and mouth disease (HFMD); periodic large epidemics
have occurred in recent decades, and it has become a se-
vere public health problem [3–9].
Previous studies have shown that EV-A71 usually
causes HFMD with severe neurological complications,* Correspondence: zhangwenyan@jlu.edu.cn; xfyu@tju.edu.cn
†Equal contributors
1Institute of Virology and AIDS Research, First Hospital of Jilin University,
No 519, East Minzhu Avenue, Changchun, Jilin 130021, China
Full list of author information is available at the end of the article
© 2015 Chang et al. This is an Open Access ar
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/including aseptic meningitis, brainstem encephalitis, polio-
myelitis, encephalomyelitis, and even death [10–20]. In
1997, a large outbreak of HFMD caused by highly neuro-
virulent EV-A71 emerged in Malaysia and led to 41 deaths
among young children [21]. In 1998, a large outbreak of
enterovirus infection occurred in Taiwan that resulted in
405 severe cases in children and 78 deaths. Of the 78 chil-
dren who died, 71 (91 %) were under 5 years of age [22]. In
2011, the largest recorded outbreak of EV-A71-associated
HFMD occurred in mainland China, comprising >1.7
million cases and including 27,000 patients who exhibited
severe neurological complications and 905 deaths [23].
EV-A71 has one serotype and can be classified into
three genotypes (A, B, and C) and many subtypes (A,
B0, B1-B5, and C1-C5). In Taiwan, the major subtypes of
EV-A71 were C2 in 1998, B4 in the 2002 epidemic, C4 in
the 2004-2005 epidemic, C5 in the 2006-2007 epidemic,
B5 in the 2008-2009 epidemic, C4 in the 2010 epidemic,ticle distributed under the terms of the Creative Commons Attribution License
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inant EV-A71 genotypes detected in Singapore were B3 in
1997-1999, B4 in 2000-2003, C1 in 2002, and B5 in 2006-
2008. In mainland China in 1998-2011, all the strains were
clustered in the C4 subgenotype of EV-A71.
Most research has been focused on developing vaccines
against EV-A71 [26–35]. Given the successful experience
in the development of inactivated whole viruses for polio-
virus, influenza virus, and rabies virus, inactivated EV-A71
whole-virus vaccines have been produced by five manufac-
turers in mainland China, Taiwan, and Singapore. These
vaccines have completed Phase III (mainland China) and
Phase I (Taiwan and Singapore), respectively [32]. In
mainland China, Beijing Vigoo Biological Co., Ltd (Vigoo),
Sinovac Biotec Co., Ltd (Sinovac), and the Chinese Acad-
emy of Medical Science (CAMS) have used EV-A71 sub-
genotype C4 as a virus seed because it is the prevalent
genotype in mainland China; however, Vigoo and Sinovac
chose distinct strains, FY and H07, respectively, which
were all isolated from Anhui province in South China
[36, 37]. Thus far, no vaccine has effectively prevented
EV-A71 infection in HFMD patients is available.
Previously, lethal mouse model in EV-A71 infection has
been a pivotal evaluation role in the development of EV-
A71 vaccines [27, 29, 33, 35]. However, EV-A71 viral iso-
lates from HFMD patients in northeastern China [38]
have not been previously studied in a mouse model or for
vaccine development. Our group has isolated and identi-
fied several circulating EV-A71 strains from hospitalized
HFMD children in northeastern China who had either se-
vere or mild disease. We determined that these strains are
complex recombinant viruses involving multiple type A
human enterovirus (HEV) [38]. In the present study,
we examined and compared the virulence, pathological
changes, and progression induced by the circulating
EV-A71 viruses, including Changchun (CC, Northeast
China) and Fuyang (FY, South China) strains, in a neonatal
mouse model. These strains showed different virulence,
and a series of lethal strains could be used as a tool for
vaccine evaluation. Furthermore, the EV-A71 vaccine can-
didate CC063 strain with the highest virulence also pre-
sented a broadly cross-neutralizing capacity and protection
to neonatal mice from lethal-dose infect with various EV-
A71 viruses. At the same time, the sera of the immunized
dams and their pups showed higher neutralization titers
against various EV-A71 viruses. The lethal challenge and
protection in mouse model from circulating primary EV-
A71 strains and the select vaccine candidates can be very
helpful for vaccine development and evaluation.
Methods
Cells and viruses
African green monkey kidney epithelial cell line, Vero
cells (Cat no. CCL-81; ATCC) were cultured in modifiedEagle’s medium (MEM) (Gibco, Invitrogen, USA) contain-
ing 10 % fetal bovine serum (FBS) (Gibco, Invitrogen,
USA) and 3 % L-glutamine at 37 °C with 5 % CO2. The
CC strains of EV-A71 viruses were isolated from throat
swabs of HFMD patients in Changchun, China in 2010.
Viruses were continuously subcultured to the tenth passage
in order to ensure stable titers and genetic features. FY0805
(GenBank accession No. HQ882182.1) and SHZH98 (Gen-
Bank accession No. AF302996.1) viruses were gifts from
Dr. Qi Jin (Institute of Pathogen Biology, Chinese Acad-
emy of Medical Science). BrCr (GenBank accession No.
U00871.1) viruses were received from Dr. PY. Mao (302
Military Hospital of China). CV-A16-CC024 is preserved
in our laboratory and was isolated from a HFMD patient
in Changchun, China (GenBank accession No. KF055238).
Viruses were harvested when the cytopathogenic effect
(CPE) reached 90 %, and the viral titers were determined
in Vero cells by the microplate CPE method and calcu-
lated by the Reed–Muench method [39].
Neonatal mouse infection model
One-day-old specific-pathogen-free (SPF) ICR neonatal
mice (Experimental Animal Center, Jilin University) were
used to establish the animal model of viral infection. All
welfare and experimental procedures were carried out
strictly in accordance with the guide for the care and
use of laboratory animals and the related ethical regula-
tions of the First Hospital of Jilin University. All efforts
were made to minimize animal’s suffering.
The neonatal mice were divided into different groups,
randomly and each group contains three litters (n = 8 ~
10 per litter), and inoculated intracerebrally with EV-
A71 viruses or MEM (10 μl/mouse), respectively. The
survival rates and mean clinical symptoms were moni-
tored daily for 21 days post-infection. The mean clinical
symptoms were scored as follows: 0, healthy; 1, lethargy
or weakness; 2, wasting; 3, limb shake; 4, paralysis in
hind limb; 5, moribund or dead. The control mice were
healthy throughout the experiments. The median lethal
dose (LD50) was calculated as described by the Reed–
Muench method [39].
Histopathological and immunohistochemical analysis (IHC)
Three mice with grade 1 to 5 of clinical disease from
each of three experimental groups, EV-A71CC063 (106.5
CCID50/ml), BrCr (10
6.5 CCID50/ml), EV-A71CC072 (10
6.5
CCID50/ml), and three mice of grade 0 to 1 from the con-
trol group were subjected to histopathological and IHC
analysis at 5 days post-infection. After the mice were anes-
thetized, tissues and organs, including lung, intestine, liver,
kidney, hind limb muscle, spleen, heart, spinal muscle and
brain, were harvested and immersion-fixed with 10 % for-
maldehyde solution for 5 days. Then, all the samples were
dehydrated via an ethanol gradient, clarified through
Chang et al. BMC Microbiology  (2015) 15:139 Page 3 of 14dimethylbenzene, and embedded in paraffin, and 4-μm
sections were obtained for hematoxylin and eosin (HE)
staining. For IHC examination, 4-μm sections of tissue
samples were dewaxed and hydrated through an ethanol
gradient. Antigens were then restored by microwaving for
15 min at 95 °C in citrate buffer. Used hydrogen peroxide
(2.5 %) treatment to inhibit endogenous peroxidase activ-
ity of the samples. EV-A71 viral antigens were detected by
anti-EV-A71 polyclonal antibody of rabbit (developed in
our laboratory) and streptavidin-peroxidase anti-rabbit
IgG kit (Fuzhou Maixin Biotechnology Development Co.,
Ltd, Fuzhou, China).
Viral loads in newborn infected mouse tissues
Injected intracerebrally with EV-A71CC063 (106.5CCID50/
ml) or control medium, 12 viral challenged mice and 3
negative control mice were then used to detecting viral
loads.
All samples including blood, lung, intestine, liver, kid-
ney, hind limb muscle, spleen, heart, spinal muscle and
brain were harvested from the experimental group (n = 3
per time point) on days 2, 4, and 6 post-infection and
from the control group (n = 3) with no challenge on day 1.
All the collected tissue samples were weighed individually
and stored at -80 °C for further viral detection. The col-
lected tissue samples were disrupted and homogenized in
sterile phosphate buffer with the freeze-thaw/grinding
method, then centrifuged. The clarified supernatants were
collected, and viral loads in the tissue supernatant and
blood were determined by real-time fluorescence quanti-
tative reverse transcriptase PCR (qRT-PCR) and the re-
sults were expressed in log10 copies/ml of blood or log10
copies/mg of tissue. The 95 % confidence interval of the
negative control values determined in various organs and
tissues were regarded as the reference value for methodo-
logical sensitivity (0 copies/mg or ml).
Inactivation, purification, and immunogenicity of EV-A71
virus candidate vaccine
The Vero cells infected by the seven strains of EV-A71
candidate virus were collected and centrifuged at 4500 × g
for 30 min; the collected supernatants were inactived
with formalin at 4 °C for 72 h. The effect of viral inactiva-
tion was tested by CPE, The inactived viruses were
concentrated by ultrafiltration, following purified on
Sepharose 4 Fast Flow gel. The protein concentration of
the final virus elution was measured with a BCA kit
(Thermo Scientific, Inc.), and the viral purity was deter-
mined by silver stain plus reagent (Bio-Rad, Inc.). The
purified, inactivated EV-A71 derived viral proteins and
negative control antigens prepared in similar fashion
were mixed with alum and 0.5 ml (10 μg/ml) of the alum
adjuvant vaccine was used for each immunization via in-
traperitoneal injection (I.p.).Seven groups (n = 8 per group) of female adult ICR mice
were immunized i.p. with a different EV-A71 vaccine can-
didate, CC063, CC072, CC077, CC080, CC085, SHZH98,
or FY0805 two times at 2-week intervals. Serum was col-
lected on the fourth week after immunization, and neu-
tralization titers against the various EV-A71 viruses were
measured by TCID50 assay in Vero cells.
Serum neutralization test
Serum neutralization titers (NTAb) were determined by
the TCID50 reduction assay in Vero cells. Isopycnic mix-
ing (50 μl/well, respectively) of the serially diluted sera
was carried out with the working concentration (100
TCID50/ml) variously circulating EV-A71 strain stocks;
the mixtures were incubated at 37 °C for 2 h in 96-well
plates. Subsequently, the Vero cells (2 × 105/ml) were
seeded onto 96-well plates (100 μl/well) for infection at
35 °C with 5 % CO2 and cultured for 7 days. The CPE of
the Vero cells was observed by light microscopy. The
highest serum dilution that could inhibit CPE in >50 % of
the wells were determined as serum neutralization titers.
Protective efficacy of vaccine-induced maternal antibody
for neonatal mice
Eight-week-old female ICR mice (n = 3, each group) were
injected i.p. with inactivated EV-A71CC063 vaccine or
negative control phosphate-buffered saline (PBS) on
weeks 0 and 2, respectively. The inactivated vaccine con-
tained 10 μg of EV-A71CC063 virus. The first injection
was 1 h after mate. After delivery, two experiments were
carried out to confirm the protective efficacy of the
humoral immune response of the EV-A71 vaccine candi-
date. First, three immunized maternal mice and their pups
in the vaccine and negative control groups were eutha-
nized, sera were collected for neutralizing antibodies as-
says against various EV-A71 strains. Second, four groups
of pups (n = 3 litters per group, and n = 8 ~ 10 per litter)
were intracerebrally challenged with different lethal doses
of EV-A71 strains on day 1. Challenged mice were moni-
tored for 21 days.
Statistical analysis
The clinical scores, viral loads, and antibody titers were
analyzed with nonparametric one-way ANOVA tests. The
survival rates were determined by log-rank test. All statis-
tical analysis were expressed as means ± the standard error
of the mean (SEM). P < 0.05 was considered significant.
Results
Establishment of a neonatal mice model using primate
EV-A71 viruses that produce strain-specific morbidity and
mortality
Although it has been determined that the dominant
strains of EV-A71 have maintained a C4 genotype since
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the development and use of a lethal animal model
employing primary EV-A71 isolates. In 2010, multiple
EV-A71 viruses (EV-A71CC063, EV-A71CC077, EV-
A71CC072, EV-A71CC080, and EV-A71CC085) were
isolated from infected HFMD patients in Northeast
China by our group and determined to be recombinant
forms of EV-A71 viruses [38]. To determine whether
these EV-A71 viruses are lethal to neonatal mice and
could be developed as a tool for vaccine evaluation, we
intracerebrally injected multiple circulating EV-A71 viruses,
i.e., CC063, CC077, CC072, CC080, CC085, FY0805, and
SHZH98, as well as prototype EV-A71 BrCr (each at 106.5
CCID50/ml), into one-day-old mice (Fig. 1). The clinical
scores and survival rates of infected mice were monitored
for 21 days. The results showed that the mice that were
infected with CC063, CC077, CC080, and FY0805 became
sick on day 4 post-infection and present a gradual aggra-
vation tropism, with a clinical score of grade 5 on days 9,
9, 7, 9, respectively; and CC063, CC080, FY0805 infected
mice all were dead by days 9, 12, 9, respectively, CC077
group had 78 % survival rate (Fig. 1). However, CC072,Fig. 1 Distinct pathogenicity of circulating CC063, CC077, CC072,
CC080, CC085, SHZH98, and FY0805 or BrCr viruses in neonatal mice.
Newborn ICR mice were infected with indicated viruse (106.5 CCID50/ml).
Negative control mice were inoculated with MEM instead of virus.
Survival rates and mean clinical scores were continually observed for
21 days after infection. The results are from three independent
experiments, and each litter contained 8-10 mice. The mean clinical
symptoms were scored as follows: 0, healthy; 1, lethargy or weakness;
2, wasting; 3, limb shake; 4, paralysis in hind limb; 5, moribund or deadCC085, SHZH98, and BrCr did not cause mortality of
the neonatal mice; the mice only showed some mild
lethargy and inactivity in the early days of infection
(mean, 2 ~ 7d) (Fig. 1). As expected, the mice of negative
control group had a grade 0 of clinical score and 100 %
survival rate.
Lethal circulating EV-A71 viruses produce dose-dependent
morbidity and mortality
Since the circulating EV-A71 viruses cause lethality in
neonatal mice, we looked further into their virulence by
measuring the LD50 of the viruses. Groups of one-day-
old mice divided as described above were injected intra-
cerebrally with 10-fold serial dilutions of CC063 (107.5 ~
103.5 CCID50/ml), CC077 (10
7.5 ~ 104.5 CCID50/ml), CC080
(106.5 ~ 103.5 CCID50/ml), or FY0805 (10
7.5 ~ 103.5 CCID50/
ml), with MEM as the negative control for each group
(Fig. 2a-d). The mice that were infected with CC063 at ti-
ters of 107.5 ~ 105.5 CCID50/ml started to show symptoms
on days 2, 3, and 4 post-infection, respectively; the symp-
toms were grade 1 and gradually became more severe
until they reached grade 5 on days 9, 9, and 12, respect-
ively (Fig. 2a). The three titers of CC063 (107.5 ~ 105.5
CCID50/ml) caused death beginning on days 5, 6, and 8,
respectively, with a 100 % mortality on days 9, 9, and 12
post-infection, respectively (Fig. 2a). For CC063 at 104.5
CCID50/ml, the virus caused a 45 % mortality in the in-
fected mice, with a reversible mean clinical score of grade
2 (Fig. 2a). CC063 at 103.5 CCID50/ml did not cause mor-
tality, and it produced only a short period of grade 1
symptoms on days 8 ~ 10 (Fig. 2a).
For CC077, the challenged mice given 107.5 CCID50/
ml, 106.5 CCID50/ml, or 10
5.5 CCID50/ml began to sicken
on days 4, 5, and 5, respectively, with a 0 %, 80 %, and
90 % survival rate (mean clinical score of grade 3), re-
spectively (Fig. 2b). The challenged mice with 104.5
CCID50/ml began to sicken on day 7 (grade 1), and no
deaths occurred during the period of observation (Fig. 2b).
The mice that were infected with CC080 in various ti-
ters all became sick on day 3 post-infection (grade 1);
after an increased tropism in clinical grade, only the
106.5 CCID50/ml group reached grade 5 on day 12,
whereas the 105.5 and 104.5 CCID50/ml groups had mean
clinical scores of grade 3 during the whole test period
(Fig. 2c). The challenged mice with 106.5 ~ 104.5 CCID50/
ml began to die on days 5, 5, and 7, respectively (0 %,
60 %, and 80 % survival rate, respectively) (Fig. 2c). In the
103.5 CCID50/ml group, no obvious symptoms or death of
the infected mice were observed (Fig. 2c).
The mice challenged with 107.5 CCID50/ml, 10
6.5
CCID50/ml, 10
5.5 CCID50/ml, or 10
4.5 CCID50/ml FY0805
began to sicken on days 4, 5, 5, and 6 (grade 1), with
100 %, 100 %, 60 %, and 10 % mortality rates by days 8, 9,
12, and 9, respectively. The mice that were infected with
Fig. 2 Circulating CC063, CC077, CC080, and FY0805 resulted in dose-related disease and mortality. One-day-old ICR mice (n = 8 ~ 10 per litter)
were intracerebrally challenged with 10-fold serial dosages of viruses. a EV-A71CC063 challenged with 103.5 CCID50/ml to 10
7.5 CCID50/ml.
b EV-A71CC077 challenged with 104.5 CCID50/ml to 10
7.5 CCID50/ml. c EV-A71CC080 challenged with 10
3.5 CCID50/ml to 10
6.5 CCID50/ml. d FY0805
challenged with 103.5 CCID50/ml to 10
7.5 CCID50/ml. Control animals were given medium instead of virus. Mortality and clinical symptoms were




5.5 CCID50/ml, and 10
5.5 CCID50/ml, respectively
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symptoms (grade 1) on days 6 to 10 and no deaths
(Fig. 2d).
In the aforementioned four experiments, no clinical
symptoms or death were observed in the negative con-
trol group (Fig. 2a-d), indicating that the disease and
death of the mice were specifically attributable to the
EV-A71 viruses.
In conclusion, the symptoms and mortality rate pro-
duced by the four pathogenic virus strains increased in a
dose-dependent manner. The median lethal doses (LD50)
for CC063, CC077, CC080, and FY0805 were about 105.0CCID50/ml, 10
7.0 CCID50/ml, 10
5.5 CCID50/ml, and 10
5.5
CCID50/ml, respectively. CC063 appeared to be the most
pathogenic strain (Fig. 2). Thus, we have identified mul-
tiple circulating EV-A71 viruses that can induce strain-
specific mortality and disease symptoms in newborn
mice.
Pathology in the mice post-infected with a lethal dose of
circulating CC063
The newborn mice challenged with any lethal dosage of
EV-A71 virus all exhibited typical clinical symptoms
such as wasting and hind-limb paralysis. To understand
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natal mice, we selected the mice infected with the cir-
culating CC063 strain, with strong virulence at the
representative endpoint of grade 5 clinical score and con-
ducted a series of pathologic analysis of multiple tissues to
reveal changes that might be related to the death of the
newborn mice. The results showed that the hind-limbFig. 3 Pathological analysis of infected newborn mice after intracerebral ch
old ICR mice were intracerebrally inoculated with EV-A71CC063 (106.5 CCID
hind-limb muscle, spine muscle, cardiac muscle, and lung tissue at 6 days p
severe necrosis in the hind-limb muscle (b) and spinal skeletal muscle (d),
(h) by HE staining. The results for non-infected mice were used as a contromuscle and spinal skeletal muscle fibers appeared severe
necrosis, including muscle bundle fracture, muscle fiber
swelling, and nuclear dissolution and shrinkage (Fig. 3b, d)
when compared to those of the non-infected mice
(Fig. 3a, c). However, no detectable pathological symp-
toms were found in the intestine, liver, spleen, kidney,
or brain (data not shown). In addition, no obviousallenge with a lethal dose (106.5 CCID50/ml) of EV-A71CC063. One-day-
50/ml) or medium (mock control). Representative images from the
ost-infection are shown. Infected mice (clinical grades 4-5) exhibited
but no obvious histological changes in cardiac muscle (f) or lung tissue
l (a, c, e, and g). Magnification, 400 ×
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(Fig. 3f, h). These results demonstrated that circulating
EV-A71CC063 has a strong tropism cause severe le-
sions in the muscle tissues.
To better understand the distribution of viral antigen
in selected tissues of CC063-infected newborn mice, we
performed IHC staining of the associated tissues of theFig. 4 Immunohistochemical (IHC) staining results for infected mice after in
A71CC063. One-day-old ICR mice were intracerebrally inoculated with EV-A
sections from mouse tissues at 6 days post-infection (grades 4-5) are show
spinal skeletal muscle (d), cardiac muscle (f), and lung tissue (h). In contrast
and g) of the non-infected mice. Magnification, 400 ×infected mice. The results showed widespread expression
of viral antigen in the tissues, including the hind-limb
muscle (Fig. 4b), spinal muscle (Fig. 4d), cardiac muscle
(Fig. 4f ), lung (Fig. 4h), and intestine, liver, brain, spleen,
and kidney (data not shown). In contrast to the patho-
logical changes in the hind-limb and spinal muscles,
which expressed widespread viral antigen, we did nottracerebral challenge with a lethal dose (106.5 CCID50/ml) of EV-
71CC063 (106.5 CCID50/ml) or medium (mock control). Representative
n. The viral antigen (arrow) was detected in the hind limb muscle (b),
, no viral antigens were detected in the corresponding tissues (a, c, e,
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No viral antigen was detected in the non-infected mice
(Fig. 4a, c, e, g), confirmed that the detection was spe-
cific. Our results suggested that even CC063 could lead
to widespread infection, but only induced pathogenesis
in the hind-limb and spinal muscles of the mice.Viral loads in selected tissues of CC063-infected mice
To further characterized the viral replication of CC063
viruses in infected mice, we determined viral loads in
various organs at various time points post-infection
(Fig. 5). Viral loads were first detected in the heart
(102.32 copies/mg), liver (102.23 copies/mg), brain (102.01
copies/mg), and blood (103.13 copies/ml) at 2 days post-
infection in the CC063-infected mice. Four days after
challenge, the virus was detected in all tested tissues.
The viral loads in various tissues of the infected mice,
including heart, liver, spleen, lung, kidney, brain, intes-
tine, spine muscle, hind-limb muscle, and blood reached
higher levels of 103.94 copies/mg, 103.46 copies/mg, 102.94
copies/mg, 103.39 copies/mg, 102.79 copies/mg, 103.11 cop-
ies/mg, 103.73 copies/mg, 104.87 copies/mg, 103.98 copies/mg,
and 105.05 copies/ml, respectively, on day 4 post-infection.
This result suggested that the virus had spread systemic-
ally by day 4 post-infection. By day 6, the viral loads in all
the tissues except the intestine had steadily increased, and
the virus copy numbers were 104.78 copies/mg, 104.54 cop-
ies/mg, 103.56 copies/mg, 104.23 copies/mg, 103.05 copies/
mg, 103.53 copies/mg, 103.10 copies/mg, 106.01 copies/mg,
105.20 copies/mg, and 105.25 copies/ml, respectively. In the
negative control mice, no viral loads were detected in se-
lected tissues, indicating that our results were specific.
The highest viral loads were found in the spinal muscle,
hind-limb muscle, and blood in the later stages (4 ~
6 days). The detection of viral loads was also consistent
with our IHC analysis (Fig. 4), suggesting that CC063 has
a strong tropism for spinal muscle and hind-limb muscle.Fig. 5 Kinetics of viral load levels in various tissues of EV-A71CC063-infecte
detected by qRT-PCR at days 2, 4, and 6 post-infection, respectively. The re
of blood] ± SD (3 mice per group, repeated 3 times). RNA samples from the
simultaneously in each qRT-PCR, and known copies of the DNA fragments
in the infected tissuesEV-A71CC063 vaccine candidate showed strongest
immunogenicity and broader cross-neutralization capacity
According to the standards of innovative vaccine devel-
opment reported by Liang et al [40], we compared an
analyzed the immunogenicity of these EV-A71 strains
including the CC strains, SHZH98, and FY0805. Eight
groups of seven mice were immunized with various EV-
A71 viruses with equal inactivated virus antigen (10 μg/
ml and 0.5 ml/mouse) according to the immunization
procedure as Fig. 6a. The antibody cross-neutralization
titer (NT) was determined by using 28 days serum in
cellular cytopathogenic effect method in vitro. As shown
in Fig. 6b, CC063 vaccine candidate generated highest
NT, and the geometrical mean (GMT) value was 311.
The mean cross-neutralization titer value (exclude CV-
A16-CC024 and BrCr) of CC072, CC077, CC080, CC085,
SHZH98, and FY0805 were 100, 83, 111, 98, 113, and 117
(GMT). Moreover, serum of CC063 generated higher NT
value against other virus strains except itself than other
vaccine candidate (Fig. 6b). Through the comprehensive
analysis of immunogenicity and broad neutralized feature,
CC063 with the strongest virulence was chosen as an eli-
gible vaccine candidate.Maternal antibody against the CC063 vaccine candidate
can broadly protect the neonatal mice from lethal virus
challenge
We hypothesized that the animal model developed in
the present study may be a useful model for EV-A71
vaccine evaluation. To examine this hypothesis, we im-
munized female mice (n = 10) with the EV-A71 inacti-
vated vaccine candidate and mated these mice after
vaccine injection (Fig. 7a). Serum samples of three im-
munized dams and their pups on day 1 were collected.
Neutralizing antibody (NTAb) titers against various EV-
A71 strains were measured. The NTAb titers of female
mice immunized against CC063, CC072, CC077, CC080,d (106.5 CCID50/ml) one-day-old ICR mice. The viral RNA copies were
sults represent the mean virus loads [(log10copies)/mg of tissue or/ml
mock-infected mice and positive virus culture medium were run
were used as standards to calculate the copy numbers of the viral RNA
Fig. 6 Serum cross-neutralization titers generated by seven EV-A71
vaccine candidates. Eight groups (n = 8 per group) of femal adult
ICR mice were immunized with EV-A71 vaccine candidates including
CC063, CC072, CC077, CC080, CC085, SHZH98, FY0805, and MEM
(negative control) twice at 2 week intervals: a Diagram of the
experimental procedure. b CC063 vaccine candidate produced
highest mean cross-neutralization titers (GMT = 311). Mean cross-
neutralization titers of the other EV-A71 strains were 100, 83, 111, 98,
113, and 117 (exclude CV-A16-CC024 and BrCr) for CC072, CC077,
CC080, CC085, SHZH98 and FY0805, separately. The values for the
negative control and CV-A16-CC024 sera were all < 8
Fig. 7 Broadly neutralizing antibody in immunized dams and pups. a Expe
inactivated EV-A71 viral preparation and subsequently examined for serum
The sera were collected from 3 dams and their pups (8 to 10 mice per gro
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of 1024, 421, 550, 487, 518, 128, 199, and 32 (GMT), re-
spectively. The NTAb titers of non-immunized mice
were not detectable (Fig. 7b). The serum NTAb titers of
pups born to the immunized female mice averaged 499,
263, 271, 247, 245, 71, 80, and 14 (GMT), respectively.
As expected, no NTAb was detected in those pups born
to non-immunized mice (Fig. 7c).
Next, we determined whether our EV-A71 vaccine
candidate could protect neonatal mice from challenge
with various lethal viruses. After delivery, we intracere-
brally challenged the pups were with lethal a dose of
CC063 (200LD50), CC077 (100LD50), CC080 (100LD50),
or FY0805 (100LD50) on day 1. The neonatal mice born
to unimmunized mice (MEM) in the four groups started
to die an average of 6 days after virus inoculation, and
all were dead by day 10 post-infection (Fig. 8a-d). In
contrast, newborn mice of maternal immunized with
vaccine candidate showed a 100 % survival rate and
expressed lower clinical scores (grade 1) in the early
stage of the tests (Fig. 8a-d). These results suggested
that the animal model developed in this study can be
used to evaluate EV-A71 vaccine candidates and that
our inactivated EV-A71 vaccine candidate offers high
efficiency and broad-spectrum cross-protection against
diverse EV-A71 viruses in a neonatal mouse model.rimental design. (b and c) Adult female mice were immunized with
neutralizing antibody titers as described in section of the Methods.
up, mixed) after delivery as described in section of the Methods
Fig. 8 Broadly protection of maternal immunization with the inactivated EV-A71CC063 against lethal viruses challenge in neonatal mice. One-day-
old ICR mice (n = 8 ~ 10 per litter) born to immunized mice were intracerebrally challenged with a CC063 (200LD50), b CC077 (100LD50), c CC080
(100LD50), or d FY0805 (100LD50) and had a 100 % survival rate during the test period of 21 days. The neonatal mice born to unimmunized mice
(positive control) in the four groups all had a 100 % mortality rate and suffered increasing grades of clinical score
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Animal models plays a critical role in the development
and evaluation of potential EV-A71 vaccines. Since nor-
mal adult mice are insensitive to EV-A71 infection, some
researchers have suggested using neonatal mice or trans-
genic mice challenged with single viruses to evaluate the
protective efficacy of vaccines [27, 29, 33, 35]. In our
study, we have identified multiple lethal circulating EV-
A71 viruses in a neonatal mouse model and have
analyzed the pathogenic features of the lethal and non-
lethal strains. These circulating EV-A71 strains were iso-
lated from different regions of China. Early genome
analysis demonstrated that these EV-A71 strains are cir-
culating recombinant viruses [38] that are distinct fromthe prototype EV-A71 (BrCr). Interestingly, although the
prototype EV-A71 (BrCr) did not cause lethal infection
in the neonatal mice, several primary EV-A71 isolates
readily generated pathogenic infections in these mice.
On the other hand, some primary EV-A71 isolates could
not cause lethal infection, despite the fact that they are
genetically closely related to the pathogenic primary EV-
A71 viruses.
Primary circulating EV-A71 viruses cause many symp-
toms in neonatal mice, including wasting, limb-shake
weakness, and hind leg paralysis. HE staining showed se-
vere lesions in the hind limb and spinal skeletal muscles,
but not in the cardiac muscles or lung tissues; these
findings are very different from those in the neonatal
Chang et al. BMC Microbiology  (2015) 15:139 Page 11 of 14mice infected with lethal CV-A16 viruses, which suffered
from severe lung damage [41]. We could also detected
viral antigen in the hind limb, cardiac, and spinal skeletal
muscles. As expected, a large amount of viral antigen
was detected in the brain tissue (data not shown), a
point that has been emphasized in many previous stud-
ies [11, 14, 17, 19, 42, 43]. Virus loads in these organs
were consistent with our results. However, the expres-
sion of viral antigen could also be detected by IHC (data
not shown) in many other tissues of the infected mice
that showed tissue-specific pathogenesis.
Several viruses, such as CC072, CC085, SHZH98, and
BrCr, were unable to induce neonatal death in the mice
(Figs. 1 and 2). Consistent with the findings, pathological
changes and viral loads could not be detected in the or-
gans of these infected mice (data not shown), suggestnig
that the absence of viral replication in the neonatal miceFig. 9 Amino acid sequences alignment of VP1 region of virulent (first fourmight be the main reason that the virus could not in-
duce animal death. Our mouse model should be useful
for future identification of viral determinants of patho-
genic infection.
Previous studies have demonstrated that 5’UTR and
VP1 may be the major virulence associated regions of
the EV-A71. We performed the 5’UTR and VP1
sequences alignment of the virulent and non-virulent
EV-A71 viruses (Figs. 9 and 10). We found that the non-
virulent EV-A71 contain mutations that are not detected
in the virulent strains. Future studies will be required to
determine whether these mutations influence virulence
of EV-A71 in the mouse model. The eight EV-A71
strains evaluated in our mouse model have been associ-
ated with various disease symptoms in human. Only EV-
A71 BrCr and CC063 have been associated with severe
neurological diseases in people. Interestingly, BrCr is) and non-virulent (last four) EV-A71 strains
Fig. 10 Nucleotide sequences alignment of 5’UTR region of virulent (first four) and non-virulent (last four) EV-A71 strains
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model. It is possible that BrCr and CC063 could use dif-
ferent cellular receptors. The presence of certain cellular
receptor in mouse allowed CC063 but not BrCr to repli-
cate in the mouse model. Although the lethal mouse
model may not be suitable for all EV-A71 strains, it is
still useful for evaluating immune responses after EV-
A71 vaccine immunization and protection of these im-
mune responses against viral infection in this sensitive
and convenient animal model.
Widespread HFMD has raised serious public health
concerns in the Asia-Pacific region [4, 8, 9]. Coxsackie-
virus 16 (CV-A16) and enterovirus 71 (EV-A71) can
both cause HFMD, major studies are focused on the lat-
ter as EV-A71 infection often associated with severe
complications, including various neurological symptoms.
Interestingly, we observed that administration of only
the higher dosage of the various EV-A71 strains (CC063
LD50 ≈ 10
5.0 CCID50/ml) could induce neonatal mouse
death, as compared to circulating CV-A16 viruses (CC024
LD50 ≈ 10
1.65 CCID50/ml) [41]. The pathogenesis induced
by EV-A71 and CV-A16 needs to be further investigated
in the future.
Our study demonstrates that primary isolates of circu-
lating EV-A71 viruses differ greatly in their ability to
elicit broad-range neutralizing antibodies. Using theseviruses isolated from diverse areas, we characterized EV-
A71 vaccine candidates with the highest virulence and
determined that these candidates, derived from virus
from Northeast China, could protect neonatal mice from
challenge with diverse lethal strains. Moreover, we found
that vaccine candidate CC063 had the highest virulence
(LD50 ≈ 10
5.0 CCID50/ml) (Fig. 2a), the strongest im-
munogenicity (Figs. 6 and 7), and the broadest cross-
protection (Fig. 8). Therefore, using a sensitive mouse
model and EV-A71 viruses, we have successfully studied
the viral pathogenesis and identified a potential vaccine
candidate.
Conclusions
Since no effective antiviral agents are available, EV-A71
vaccine will play an important role in controlling EV-
A71-induced HFMD in children. The selection of a vac-
cine candidate strain is the crucial factor, especially for
the EV-A71 vaccine, because of its high mutation rate
and frequent recombination [44]. In general, the virus
vaccine candidate strain should have higher virulence,
better immunogenicity, broad cross-protection, and gen-
etic stability [37]. For vaccine evaluation, with the excep-
tion of the cellular CPE method in vitro, animal model
systems can serve directly evaluation to protective effi-
cacy and immunogenicity of candidate vaccines. Indeed,
Chang et al. BMC Microbiology  (2015) 15:139 Page 13 of 14we observed high immunogenicity of the EV-A71 vac-
cine candidate both in vitro and in vivo. Even more im-
portant is the fact that the EV-A71 candidate vaccine in
our study demonstrated broad cross-protection against
lethal challenge with multiple EV-A71 viruses from the
Jilin and Anhui provinces of China. Our study therefore
provides important guidance for future HFMD vaccine
development and evaluation which may lead to the dis-
covery of potential vaccine candidates for the prevention
and control of HFMD.
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